Abstract
In the present review we integrated findings from microarray analyses of anticonvulsant treatment, discussing the replicability of the findings and their corroboration with data obtained from patients and with information from other fields of study. We further relate to the duality of several antiepileptic drugs exhibiting both anticonvulsant and moodstabilizing effects in the treatment of epilepsy and bipolar disorder, respectively.
Keywords: Epilepsy, anticonvulsants, microarrays, mood-stabilizers, Epileptic Tissue, Cytoprotection, gene expression, multiple sclerosis, inhibitory synapses, mood-stabilizing drugs, glutamate-induced apoptotic cell death, Antidepressants, ectopic granule cells, mood disorders, GABAergic dysfunction
Current Psychopharmacology
Title:Microarray Studies in Understanding the Mechanism of Action of Antiepileptic Drugs
Volume: 1
Author(s): Lilach Toker, RH Belmaker and Galila Agam
Affiliation:
Keywords: Epilepsy, anticonvulsants, microarrays, mood-stabilizers, Epileptic Tissue, Cytoprotection, gene expression, multiple sclerosis, inhibitory synapses, mood-stabilizing drugs, glutamate-induced apoptotic cell death, Antidepressants, ectopic granule cells, mood disorders, GABAergic dysfunction
Abstract: In the present review we integrated findings from microarray analyses of anticonvulsant treatment, discussing the replicability of the findings and their corroboration with data obtained from patients and with information from other fields of study. We further relate to the duality of several antiepileptic drugs exhibiting both anticonvulsant and moodstabilizing effects in the treatment of epilepsy and bipolar disorder, respectively.
Export Options
About this article
Cite this article as:
Toker Lilach, Belmaker RH and Agam Galila, Microarray Studies in Understanding the Mechanism of Action of Antiepileptic Drugs, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040327
DOI https://dx.doi.org/10.2174/2211556011201040327 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
PD-1 Inhibitors in Neuroprotection: Modulating Neurotransmitter Pathways for Therapy
Programmed cell death protein-1 (PD-1) inhibitors, widely recognized for their role in immunotherapy, have recently emerged as potential neuroprotective agents. Beyond their traditional application in oncology, PD-1 inhibitors influence neuroimmune interactions, impacting neurotransmitter pathways critical for maintaining brain homeostasis. Dysregulation of these pathways is implicated in neurodegenerative and neuropsychiatric disorders, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Recent Update on Pathophysiology and Therapeutic Interventions of
Alzheimer’s Disease
Current Pharmaceutical Design Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders
Current Molecular Medicine Mygalin: A New Anticonvulsant Polyamine in Acute Seizure Model and Neuroethological Schedule
Central Nervous System Agents in Medicinal Chemistry Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Pharmacological Approaches for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry Cannabis: A Treasure Trove or Pandora's Box?
Mini-Reviews in Medicinal Chemistry Nicotinic Receptor Mutant Mice in the Study of Autonomic Function
Current Drug Targets - CNS & Neurological Disorders Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Age-Specific Impairment of Morris Water Maze Performance Following Neonatal Exposure to Magnetic Resonance Image in Rats
Current Neurovascular Research Recent Development in Substituted Benzothiazole as an Anticonvulsant Agent
Mini-Reviews in Medicinal Chemistry